Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin’s Lymphoma That is Recurrent or Did Not Respond to Previous Therapy

Inclusion Criteria:

Histologically confirmed Hodgkin's lymphoma at time of relapse or disease progression, meeting all of the following criteria:

Stage I-IV disease
No morphologically unclassifiable disease

Meets 1 of the following criteria:

Mixed cellularity
Lymphocytic depletion (LD)
LD, diffuse fibrosis
LD, reticular
Lymphocyte predominance (LP)
LP, diffuse
LP, nodular
Nodular sclerosis (NS)
NS, cellular phase
NS, lymphocytic predominance
NS, mixed cellularity
NS, LD
Not otherwise specified

Primary refractory disease OR disease in first relapse, except for the following:

Patients who achieved a complete response after treatment on protocol COG-AHOD0431 who experience a biopsy-proven recurrence after doxorubicin hydrochloride, vincristine, prednisone, and cyclophosphamide without involved-field radiotherapy
Patients on the observation-only arm of protocol COG-AHOD0431
Any measurable, focal mass lesion of a visceral organ (e.g., liver, spleen, or kidney)

Patients with metastatic disease to bone marrow and granulocytopenia, anemia, and/or thrombocytopenia are allowed provided both of the following criteria are met:

Platelet count ≥ 20,000/mm³ (platelet transfusion allowed)
Hemoglobin ≥ 8 g/dL (packed red blood cell transfusion allowed)
Karnofsky performance status (PS) 60-100% (for patients > 16 years of age) OR Lanksy PS 60-100% (for patients =< 16 years of age)
Life expectancy >= 2 months
Absolute neutrophil count >= 1,000/mm^3
Platelet count >= 75,000/mm^3 (transfusion independent) (for patients with no bone marrow involvement)
Creatinine =< 1.5 times upper limit of normal (ULN)
Creatinine clearance or radioisotope glomerular filtration rate >= 70 mL/min/1.73 m^2
AST and ALT =< 2.5 times ULN
Bilirubin =< 1.5 times ULN
Shortening fraction >= 27% by echocardiogram OR LVEF >= 50% by gated radionuclide study
Patients with a seizure disorder are eligible if on a nonenzyme-inducing anticonvulsant and seizures are well controlled
No CNS toxicity > grade 2
No serious intercurrent illnesses
No known hypersensitivity to E. coli-derived proteins, filgrastim (G-CSF), or any component of the study drugs
No peripheral neuropathy > grade 1
No known hypersensitivity to bortezomib, boron, or mannitol

No other concurrent chemotherapy or immunomodulating agents (including steroids)

Concurrent corticosteroids allowed for treatment or prophylaxis of anaphylactic reactions
No dexamethasone or aprepitant as an antiemetic
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
Recovered from prior therapy
No prior bortezomib or other proteasome inhibitors
At least 3 weeks since prior chemotherapy (4 weeks for nitrosoureas)
More than 14 days since prior investigational drugs

No concurrent enzyme inducing anticonvulsants that alter p450 metabolism, including phenytoin, carbamazepine, phenobarbital, or other anticonvulsants

Benzodiazepine or gabapentin allowed